Physician profile
Lian Jen
NPI 1326031048
$4,755.92
in general payments reported to CMS, 2019-2025
23 companies · $584 in 2025
The $584 reported for 2025 was more than what 81% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $465 · 2021: $825 · 2022: $933 · 2023: $753 · 2024: $666 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,003.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,558.75 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $693.72 | 2019-2025 | Belbuca, Xtampza |
| Indivior INC. | $525.27 | 2019-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $425.84 | 2019-2025 | Relistor |
| Pfizer INC. | $391.63 | 2019-2025 | |
| Orexo US, INC. | $272.34 | 2019-2024 | Zubsolv |
| Biohaven Pharmaceuticals, INC. | $239.65 | 2021 | |
| Amgen INC. | $116.47 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.52 | 2022 | |
| Redhill Biopharma INC. | $69.25 | 2021-2023 | Movantik |
| Eisai INC. | $57.90 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $48.52 | 2022-2023 | Ztlido |
| Upsher-Smith Laboratories LLC | $46.24 | 2019 | |
| Biodelivery Sciences International, INC. | $42.75 | 2019-2020 | |
| Ibsa Pharma INC. | $30.65 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $30.52 | 2019-2020 | |
| Daiichi Sankyo INC. | $26.71 | 2019 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Zyla Life Sciences, INC. | $20.90 | 2020 | |
| Azurity Pharmaceuticals, INC. | $16.22 | 2024 | |
| Braeburn INC. | $14.45 | 2023 | Brixadi |
| Merck Sharp & Dohme LLC | $14.18 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lian Jen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.